SUV39H1 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-SUV39H1 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificitySUV39H1
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
FormatProtein G purified
Size0.05 mg, 0.1 mg
Concentrationn/a
ApplicationsELISA (EIA), Immunohistochemistry (IHC)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionHistone methyltransferase that specifically trimethylates 'Lys-9' of histone H3 using monomethylated H3 'Lys-9' as substrate. Also weakly methylates histone H1 (in vitro). H3 'Lys-9' trimethylation represents a specific tag for epigenetic transcriptional repression by recruiting HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones. Mainly functions in heterochromatin regions, thereby playing a central role in the establishment of constitutive heterochromatin at pericentric and telomere regions. H3 'Lys-9' trimethylation is also required to direct DNA methylation at pericentric repeats. SUV39H1 is targeted to histone H3 via its interaction with RB1 and is involved in many processes, such as repression of MYOD1-stimulated differentiat
ImmunogenImmunogen: Recombinant human Histone-lysine N-methyltransferase SUV39H1 protein
Other Names[Histone-lysine N-methyltransferase SUV39H1; Histone H3-K9 methyltransferase 1; H3-K9-HMTase 1; Lysine N-methyltransferase 1A; Position-effect variegation 3-9 homo; SUV39H1; KMT1A; SUV39H]
Gene, Accession #[SUV39H1], Gene ID: 6839, NCBI: NP_001269095.1, UniProt: O43463
Catalog #MBS7043637
Price$160, $235
Order / More InfoSUV39H1 Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.